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Diesel particulate matter (DPM) has adverse health effects. Examining the underlying pathophysiological mechanisms would be
facilitated by the introduction of an exposure method that is safe, portable, and cost-effective. The purpose of this study was to
establish a novel method to study DPM exposure via nebulization and an inhalation dose that was safe, yet capable of eliciting
an inflammatory response. Ten participants enrolled in this nonblinded, nonrandomized study. Subjects inhaled nebulized 0.9%
saline and increasing doses of DPM suspended in 0.9% saline (75, 150, and 300𝜇g) in a sequential manner. FEV
1
was measured
repeatedly during the first 2 h after exposure and blood, oximetry, sputum, and heart rate were taken before, 2 h, and 24 h after
inhalation challenge. DPM inhalation was well-tolerated at all doses. A decrease in FEV
1
was observed after each inhalation
challenge (including saline). Inhalation of 300 𝜇g DPM produced a significantly different FEV
1
response curve. An increase in
particle inclusion-positive sputummacrophages for all DPM doses confirmed that the nebulized particles were reaching the lower
airways. SerumGM-CSFwas elevated after exposures to 150 and 300 𝜇gDPM.No other inflammatory changes were detected. DPM
inhalation via nebulizer is a safe method of delivering low doses of DPMs in healthy people.
1. Introduction
In a variety of epidemiological and experimental studies,
researchers have demonstrated that respiratory exposure to
airborne pollutants is associated with systemic sequelae that
can not only have effects on the respiratory tract itself but also
create fertile conditions for the development of atherosclero-
sis, plaque destabilization, atherothrombosis, and consequent
cardiovascular events [1–3]. Diesel particulate matter (DPM)
is a significant component of airborne particulate matter,
as diesel engines are widely used in modern industry and
transportation; DPM contains substances that can pose a risk
to human health, and the particles themselves are readily
respirable and penetrate into the alveolar spaces. DPM is
widely used as an experimental model for particulate air
pollution for several reasons: they are a common real-life pol-
lutant; they are chemically and physically well-characterized;
standardized material is available; and the existing literature
on DPM exposure (in cultures, animal models, and humans)
gives us a broad knowledge base from which to base our pro-
tocols and expectations [4–7].
There are a few existing models for human experimental
exposures to DPMs. The most common protocol is to direct
exhaust from a diesel engine into an exposure chamber.
Although very effective, the disadvantage of this system
is the elaborate, fixed setup, which is expensive to build
and operate. Nasal instillation of DPM is a less expensive
method which induces local inflammation in the nasal lavage
fluid [6], increases in IgE [5, 7], and augments allergen-
induced responses in the nasal passages [7]. This method is
inexpensive and simple but does not deliver the particles to
the lower respiratory tract.
Nebulization of particles has not been described in the
literature for use in human subjects, although it is frequently
used in animal studies. If established as safe and effective,
inhalation of nebulized DPM would be an inexpensive and
simple method to facilitate health research on the effects of
particulates in the lungs and systemically. In this safety trial,
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Table 1: Subject characteristics.
Subject FEV1 FVC Gender Age
1 3.1 3.8 F 35
2 3.9 5.6 M 38
3 3.2 4.1 F 32
4 3.2 3.8 F 34
5 3.7 4.5 F 38
6 3.2 3.5 F 19
7 3.4 4.1 F 19
8 3.7 4.1 F 21
9 2.4 3.2 F 38
10 3.9 4.5 F 23
we examined whether DPM exposure via nebulization is safe
for experimental study, aiming to identify the lowest effective
dose of DPMs capable of reliably eliciting inflammatory
responses in the airways and blood.
2. Methods
2.1. Subjects. Twelve healthy subjects were enrolled in the
study (female: 10; male: 2). Prior to study entry subjects were
examined by a physician to confirm their overall good health.
This included a physical exam and blood work, assessing
C-reactive protein (CRP) levels, kidney and liver function,
and (for female subjects) a pregnancy test. Subjects were
excluded from the study if their baseline CRP levels were
above 3mg/L, they were pregnant, or for any other health
consideration identified by the examining physician. Subjects
were nonsmokers, were not using any medication other than
birth control, and had not experienced respiratory infection
within the previous six weeks. Two subjects (1 male; 1 female)
were excluded during screening due to high levels of serum
CRP. All subjects were instructed to refrain from taking over-
the-counter nonsteroidal anti-inflammatories for two weeks
prior to and during the course of the study. See Table 1 for
subject characteristics.
2.2. Study Design. As it was primarily a safety trial, this
studywas a nonrandom, nonblinded design consisting of four
arms. Subjects were required to come into the laboratory on
thirteen separate sessions. Visit one was the screening visit,
with the following twelve sessions comprising the four arms
of the study. For each arm, subjects visited the laboratory
for three consecutive days. Each arm was separated by a
minimum of 7 days and all visits occurred in the morning
within 1 hour of each other to minimize circadian variations.
A physician was onsite during all study visits and examined
patient results prior to continuing with the next inhalation
challenge.
For each arm of the study, on study day 1 (baseline),
subjects were asked if they had any medical issues since the
last visit and it was confirmed that they had not taken any
medications prior to their sessions. Baseline spirometricmea-
surements (FEV
1
, FVC), pulse rate, and pulse oximetry were
taken followed by sputum induction and blood sampling.
On day 2, baseline spirometry was repeated, followed by the
inhalation of the nebulized saline or DPM. After inhalation
challenge, pulse rate, pulse oximetry, spirometric measure-
ments, and a symptoms questionnaire were measured for 2 h,
at which time blood sampling and sputum induction were
performed. On day 3, all the measurements taken on day 1
were repeated.
This study protocol was approved by the Laurentian Uni-
versity Ethics Board, and all subjects provided written, infor-
med consent prior to participation in the study.
2.3. Diesel ParticulateMatter. StandardizedDPM(SRM2975)
was obtained from the National Institute of Standards and
Technology (Gaithersberg, MD, USA). The standardized
DPM was collected from the exhaust of a diesel forklift and
hot bag filter system, as described in the certificate of analysis
for this material [8]. DPM was suspended in 3mL of 0.9%
saline. DPM solutions were diluted and sonicated using a
SonicDismembratorModel 500 (Fisher Scientific) 20mprior
to inhalation challenge. The top dose used in our study,
300 𝜇g, was selected based on the work of Diaz-Sanchez
et al., who administer this amount to human subjects by
intranasal instillation and is roughly equivalent to breathing
Los Angeles air for 24 h or 30 s of breathing standing in close
proximity to an operating diesel engine [7].
2.4. Inhalation Challenge. The AeroEclipse II Breath Actu-
ated Nebulizer (Monaghan Medical Corporation, Platts-
burgh, NY, USA) was used for inhalation challenge. 3mL
of either 0.9% saline or a mixture of 0.9% saline with DPM
doses of 75𝜇g, 150 𝜇g, and 300 𝜇g (DPM75, DPM150, and
DPM300) was placed into the nebulizer cup (final conce-
ntrations of 25, 50, and 100 𝜇g/mL, resp.). The nebulizer was
set to “breathe actuated” mode to ensure subjects inhaled the
entire dose. The flow meter, attached to medical air, was set
to 50 P.S.I. with a flow of 8 liters per minute. Subjects wore a
nose plug and were asked to inhale and exhale through the
nebulizer at a normal breathing pace until the entire solution
was gone.
2.5. Oximetry & Pulse Rate. Oximetry and pulse rate were
measured using a SuperSpiro Spirometer that was equipped
with a Nonin SpO
2
probe (Micro Medical Ltd., Kent, UK).
Oximetry and pulse rate were measured concurrently on day
1 and at 2min, 30min, 2 hours, and 24 hours after inhalation.
2.6. Spirometry. Spirometry was performed with a Super-
Spiro Spirometer V1.05 (Micro Medical Ltd., Kent, UK)
according to the American Thoracic Society standards [9].
FEV
1
and FVC were repeated a minimum of three times,
selecting the best effort. Spirometry was also performed after
each inhalation challenge and at 10, 20, 30, 45, 60, 90, and
120min after inhalation challenge.
2.7. Symptoms Questionnaire. An eight-question symptom
score questionnaire was administered at 2 h after inhalation,
querying the subjects’ experience of: headache, nausea, dizzi-
ness, difficulty concentrating, fatigue, weakness, heart rate,
and dyspnea.
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Table 2: Total cell counts following inhalation of saline, DPM75, DPM150, and DPM300 (×106 cells/g).
Baseline 2 h 24 h
Saline 7.5 ± 2.78 4.7 ± 1.43 5.1 ± 1.25
DPM 75 6.2 ± 1.36 3.6 ± 0.79 5.3 ± 0.10
DPM 150 13.0 ± 9.11 3.4 ± 0.59 3.7 ± 0.12
DPM 300 5.3 ± 1.00 5.5 ± 1.55 9.0 ± 0.35
Values given as mean ± SEM. No significant differences between time or groups was found.
2.8. Sputum Induction/Processing. Sputum was induced by
inhalation of a hypertonic saline mist and processed accord-
ing to Pin et al. [10] and modified according to Pizzichini
et al. [11]. Briefly, subjects inhaled 3, 4, and 5% aerosolized
saline for 7min each, expectorating between each, until
sufficient sample was obtained. Sputum plugs were selected
from the expectorate, and if sufficient quantity was obtained
(approximately 200mg), cell smears were prepared and
stained with DiffQuik (Fisher Scientific). Differential cell
counts were performed by counting 400 nonsquamous cells
from duplicate slides. In a subsequent reading of the same
slides, macrophages were subdivided into those with no
visible particle inclusions (negative), those with fewer than
20 inclusions (low-positive), and those with more than 20
inclusions (high-positive), as described by Mukae et al. [12].
All counts were performed by a technician blinded to the
subject and exposure status.
2.9. Peripheral Blood Collection/Analysis. Venous blood sam-
ples were obtained at baseline and 2 and 24 hours after
inhalation challenge. Complete blood counts (CBC), erythro-
cyte sedimentation rate (ESR), international normalized ratio
(INR), and C-reactive protein (CRP) measurements were
performed by LifeLabs Medical Laboratory Services. Blood
serum was separated by centrifugation and stored at −80∘C.
IL-6, GM-CSF, and IL-8 protein levels were quantified using
commercially available ELISAs (eBioscience, USA, and BD
OptEIA, Canada, resp.). The limits of detection for IL-6 and
GM-CSF were approximately 2 pg/mL.The limit of detection
for IL-8 was approximately 3.1 pg/mL. Values below the limit
of detection were assumed to be 0 pg/mL for statistical
analysis.
2.10. Statistics. Summary statistics were expressed as mean
± SEM. Data were analyzed using repeated measures (rm)
ANOVA (between group analysis: saline versus DPM75 ver-
sus DPM150 versus DPM300; within group analysis: before
versus 2 hr after versus 24 hr after inhalation). Statistical
significance was accepted as 𝑃 < 0.05.
3. Results
3.1. Inhalation-InducedAirway Responses. Baseline FEV
1
val-
ues were similar on all study days. During the two hours
after inhalation challenge, there was a significant decrease
in the mean maximal fall in FEV
1
from baseline after all
challenges (𝑃 < 0.05) (Figures 1(a)–1(d)). The percent mean
maximal falls in FEV
1
from baseline were 3.6 ± 0.97%, 3.0 ±
0.62%, 4.7 ± 0.95%, and 6.2 ± 1.81%, for saline, DPM75,
DPM150, and DPM300, respectively. All of the maximum
falls in FEV
1
occurred within 45min of inhalation. These
declines were transient for all doses, with FEV
1
statistically
indistinguishable from baseline by 90min after inhalation.
When comparing the mean maximal fall in FEV
1
between
inhalation challenges, the 300 𝜇g dose was statistically signif-
icantly different from the saline and 75 𝜇g doses (Figure 1(e))
(𝑃 < 0.05).
3.2. Sputum Cell Counts
Total Cell Counts. Baseline values were similar on all study
days. Following inhalation challenge, there were no signifi-
cant changes in the total cell counts at 2 or 24 hours compared
to baseline for any of the challenges.There were no significant
differences in total cell counts between groups (Table 2).
Following inhalation challenge, there were no significant
differences in the total number of or in the percent change
in neutrophils, macrophages, or eosinophils at 2 or 24 hours
compared to baseline for all of the challenges (data not
shown). There were no significant differences in the number
or percentage of these cells between groups.
3.3. Sputum Macrophage Particle Inclusions. The majority
of sputum macrophages (80–90%) had no visible particle
inclusions in all groups at all time points (data not shown).
The majority of sputum macrophages with visible particle
inclusions fell into the “low-positive” category (i.e., fewer than
20 inclusions) with the proportion of “high-positive” (i.e.,
more than 20 inclusions) sputum macrophages under 0.5%
of total sputum macrophages (data not shown). Thus, for the
purposes of analysis, the “low-positive” and “high-positive”
macrophages were grouped together (Figure 2).
At baseline, approximately 10–13% of sputum macro-
phages had particle inclusions (Figure 2). After inhalation
challenge with DPM, the proportion of macrophages with
particle inclusions increased significantly at 2 h compared to
baseline (𝑃 < 0.05), approaching 20% for all DPM doses.
At 24 h after DPM exposure, particle inclusions in sputum
macrophages remained slightly elevated but remained statis-
tically significant only for the 150𝜇g dose.
3.4. Blood Analysis
White Blood Cell Count. Baseline values were similar on all
study days. Following inhalation challenge, there were no
significant changes in WBC at 2 or 24 hours compared to
baseline for all of the challenges and no significant differences
between groups (data not shown).
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Figure 1: Change in forced expiratory volume per second (FEV
1
) following inhalation of saline (a), 75 𝜇g (b), 150 𝜇g (c), or 300 𝜇g DPM
(d). Data in (a)–(d) are shown as mean ± SEM. (e) is an overlay of the curves from (a)–(d) for comparison of means. In (a)–(d), ∗significant
decrease in FEV
1
from baseline (BL) by 1-way repeated measures ANOVA; †significant difference from 24 h by 1-way repeated measures
ANOVA. In (e), ∗significant difference between the doses by repeated measures ANOVA.
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Figure 2: Percent of sputummacrophageswith particle inclusions at
baseline (BL), 2 h, and 24 h after exposure to saline or varying doses
of DPM. Data are shown as mean ± SEM. ∗Significant change from
baseline by repeated measures ANOVA.
Following inhalation challenge, there were no significant
differences in the total number of neutrophils, monocytes,
eosinophils, or platelets at 2 or 24 hours compared to baseline
for all of the challenges and no significant differences between
groups (data not shown).
Baseline values for erythrocyte sedimentation rate, pro-
thrombin time, and C-reactive protein were similar on all
study days. Following inhalation challenge, there were no
significant changes in either measure at 2 or 24 hours com-
pared to baseline for all of the challenges and no significant
differences between groups (data not shown).
3.5. Sputum Supernatant and Serum Assays
Interleukin-8 in Sputum Supernatant. Baseline values were
similar on all study days. Following inhalation challenge,
there were no significant changes in IL-8 at 2 or 24 hours
compared to baseline for saline, DPM150, or DPM300.There
was a significant decrease from baseline at the 2 h time point
for DPM75 (𝑃 < 0.05) (data not shown). When comparing
inhalation challenges, we found a significant decrease in IL-
8 at 2 h after inhalation of DPM300 compared to saline, but
not for DPM75 andDPM150.We found a significant decrease
in IL-8 at 24 h after inhalation of DPM75 compared to saline
and DPM150; no other significant difference between groups
at 24 h after inhalation challenge was found (data not shown).
Interleukin-8 in Serum. In the serum, baseline values were
similar on all study days. Following inhalation challenge,
there was a significant decrease in IL-8 from baseline for
DPM150 at 2 h and 24 h (BL: 6.5 ± 1.78; 2 h: 2.3 ± 0.61;
24 h: 1.5 ± 0.66) but not for DPM75 or DPM300 (data not
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Figure 3: Serumgranulocytemacrophage colony-stimulating factor
(GM-CSF) levels measured by ELISA at baseline (BL), 2 h, and 24 h
after exposure to saline or varying doses of DPM. Data are shown as
mean ± SEM. ∗Significant difference from baseline and †significant
difference from saline at a given timepoint, as determined by
repeated measures ANOVA.
shown). When comparing inhalation challenges, there was
significantly less IL-8 at 2 and 24 h after inhalation ofDPM150
compared to saline, DPM75, and DPM300; there were no
other significant differences in IL-8 between groups.
Interleukin-6 in Sputum Supernatant. There were no signif-
icant changes in IL-6 at 2 or 24 h compared to baseline for
any dose, nor were there any differences between inhalation
challenges between groups.
Interleukin-6 in Serum. There were no significant changes in
IL-6 at 2 or 24 h compared to baseline for any dose, nor were
there any differences between inhalation challenges between
groups.
Granulocyte/Macrophage-Colony Stimulating Factor in Spu-
tum Supernatant. There were no significant changes in GM-
CSF at 2 or 24 hours compared to baseline for any dose,
nor were there any differences between inhalation challenges
between groups.
Granulocyte/Macrophage-Colony Stimulating Factor in
Serum. The baseline value for DPM300 was significantly
greater than the saline and DPM75 dose (Figure 3). At 2 h
after inhalation of DPM150, we found a significant increase
in GM-CSF compared to saline, DPM75, and DPM300. At
24 h after inhalation of DPM150 and DPM300, we found
a significant increase in GM-CSF compared to saline and
DPM75.
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3.6. Oximetry & Pulse Rate. Baseline values were similar on
all study days. Following inhalation challenge, there were no
significant changes in blood oxygen saturation or pulse rate
at 2min, 30min, 2 h, or 24 h compared to baseline for all of
the challenges (data not shown).
3.7. Symptom Questionnaire. None of the subjects reported
any serious adverse symptoms during the saline inhalation
challenge. Following inhalation challenge of DPM75, 3 sub-
jects answered positively to the symptoms questionnaire:
1 subject said that they felt both mild nausea and had a
mild headache, 1 subject said they felt mild dizziness, and 1
subject said they experienced mild weakness. At DPM150 1
subject answered positively to the symptoms questionnaire,
saying they experienced mild fatigue. At DPM300, 4 sub-
jects answered positively to the symptoms questionnaire: 1
experienced mild headache and mild fatigue; 1 experienced
mild headache, mild weakness, and mild difficulty breathing;
1 experienced mild fatigue and mild difficulty concentrating;
and 1 respondent experienced mild fatigue. None of these
symptoms for any of the 4 arms were statistically significant.
One symptom that was not on the questionnaire that was
spontaneously reported by subjects was a scratchy throat: 6
out of 10 subjects reported a mild scratchy throat at DPM300.
4. Discussion
Our findings establish that inhalation of nebulized DPM
mixed in saline via a nebulizer is a safe and effective
method for research on the local and systemic effects of
particulate matter in healthy human subjects. Inhalation of
DPM using this method induced declines in FEV
1
and some
mild symptoms such as nausea, dizziness, fatigue, headache,
and a scratchy throat. We also saw evidence that the DPM
reached the lower airways through an increase in the positive
macrophage particle inclusions and evidence of systemic
effects with an increase in GM-CSF in the blood serum. To
our knowledge, this is the first published study of the isolated
effects of DPM using nebulization as a delivery method. As a
pilot study, with safety being the paramount concern, we used
a nonrandom, nonblinded design, so that we could establish
the tolerability of each dose in each subject before escalating
the dose further.
We observed small but significant decreases in FEV
1
following all inhalation challenges, which were transient
and returned to baseline by the 24 h time point. We were
somewhat surprised to see a small decrement in FEV
1
after
inhalation of saline, as we would expect that in healthy
individuals, we would not see any change in FEV
1
after
isotonic, hypotonic, or hypertonic saline inhalations [13].
However, it is known that inhalation of saline can cause
airway constriction in people with asthma [14]. Our subjects
were screened for airway disease by questionnaire, but we
did not perform methacholine challenge on them to test for
airway hyperresponsiveness. Thus, it is possible that a subset
of our subjects had undiagnosed asthma andwere thus hyper-
responsive, resulting in the observed decrement in FEV
1
after inhalation of saline only. Inhalation of nebulized DPM
resulted in a small but statistically significant drop in FEV
1
in
healthy humans; it is reasonable to hypothesize that theremay
be amore severe problem in subjects who have an underlying
pulmonary disease or airway hyperresponsiveness [15, 16].
We therefore would recommend that, in addition to the
safety measures that we took during this study, all subjects be
prescreened with methacholine challenge, particularly if this
method was to be performed in a population with allergy or
asthma.
Our findings indicate that DPM exposure has acute
effects on lung function of healthy individuals, in contrast
with what has been reported by others [4, 17–20]. In contrast,
lung function declines have been documented in people with
asthma exposed to DPM. For example, McCreanor et al. [15]
observed a decrease in FEV
1
in mild andmoderate asthmatic
subjects who were exposed to diesel exhaust for 2 h in a street
setting. Interestingly, the FEV
1
drop that we observed at the
300 𝜇g dose of DPM was comparable in magnitude to that
found byMcCreanor et al. (6.1% versus 6.2%, resp.). In a real-
life setting, people do inhale concentrations of particulates,
similar to the doses we used, in short periods of time, for
example, standing behind a bus when it is started or in some
occupational settings. Thus, the ability of DPM to induce a
decrease in FEV
1
in healthy humans in a real life setting is
unclear, but our findings indicate that it is able to do so, at
least under experimental conditions.
The doses used in this study did not elicit a lung inflam-
matory response as measured in induced sputum, in contrast
with other human exposure studies [4, 17–20]. Nightingale et
al. [4] were the first group to look at the isolated health effects
of DPM in the lower airways after a controlled inhalation
exposure in humans andmeasured an inflammatory response
in sputum. However, differences in experimental design may
explain this disparity, as our subjects received a single acute
dose of an exact dose of DPM by nebulization, while in the
Nightingale study, subjects inhaled a lower concentration
over a 2 h time period, resulting in a similar overall dose
but inhaled over very different periods of time. It may be
that nebulization over a short period results in a different
pattern of deposition of particles in the airways as compared
to inhalation of a similar dose in an exposure chamber over
a longer period of time. An alternative explanation is that we
did not look at an appropriate time point. Nightingale et al.
saw changes at 4 hours that did not persist at 24 hours after
inhalation. We measured airway inflammation at 2 and 24
hours after inhalation, and it is possible that inflammatory
changes occurred between these time points that we did not
capture.
The lack of inflammation we observed cannot be
attributed to a failure of the nebulized DPM to reach the
lower airways, as we measured a significant increase in
particle-containing macrophages in the sputum after DPM
exposure. This not only demonstrates that the particles
reached the alveoli but is also significant because alveolar
macrophages phagocytosing particulate matter can release
cellular mediators, which can stimulate the bone marrow,
indirectly signaling an inflammatory response [12]. Others
have suggested that alveolar macrophages can release some
of their lysosomal contents (ROS) when in direct contact
with particles or during phagocytosis, which can also lead to
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inflammation indirectly [21]. Although we did not measure
a cellular inflammatory response after any dose of DPM
inhaled, it seems likely that the dose of particulate that
reached the lungs was not sufficient to stimulate the alveolar
macrophages to a significant extent; this is supported by
other research that shows a dose response associated with
macrophage responses to DPM [12]. In this study, only a
tiny fraction of alveolar macrophages were “high-positive”
for particle inclusion, even after the DPM300 inhalation
challenge (0.2 ± 0.08% at 2 h, compared to 0 in the saline
group). Induction of measureable inflammatory responses
may require a larger dose or longer exposure in order to stim-
ulate airway resident cells such as alveolar macrophages (or
airway epithelial cells) to release proinflammatory mediators
or ROS and generate an inflammatory response.
Not surprisingly in the absence of notable local inflamma-
tion, inhalation of nebulizedDPMdid not induce discernable
systemic cellular inflammation after inhalation of DPM.
However, we did see a significant increase in serum levels of
GM-CSF at 2 h following inhalation of DPM150, and serum
GM-CSF levels were significantly elevated 24 h after exposure
to DPM150 and DPM300 (Figure 3). Our observations are
consistent with in vitro studies examining the effects of DPM,
which have shown increases in GM-CSF [22]. Moreover, Van
Eeden et al. have measured increased levels of circulating
GM-CSF in healthy soldiers exposed to forest fires with
the predominant pollutant being particulate matter [23]; the
increases we observed were small in comparison; however,
our DPM doses are also relatively low and DPM has a differ-
ent chemical composition than the particulates derived from
forest fires. However, given the lack of cellular inflammation
at the time points we measured, these small increases in
GM-CSF may not be sufficient to induce a measureable
inflammatory response.
This increase in serumGM-CSF, however, was not accom-
panied by an increase in sputum supernatant GM-CSF or in
granulocyte levels in the sputum or blood. Increased levels of
GM-CSF generally have not been detected in the supernatant
following sputum induction [24], although increased levels
have been evident when using bronchoscopy after inhalation
of similar DPM doses [25]. Alternatively, it is possible that
our inability to measure changes in granulocytes may be due
to the time points selected for sampling or simply that these
doses ofDPMhad a relatively small effect on the levels ofGM-
CSF produced.
The increased level of GM-CSF present at baseline in
the DPM300 might suggest that the increase in serum GM-
CSF persisted for at least one week after inhalation and
that our wash-out period needed to be longer. However,
given that there were no other indicators of a persistent
inflammatory response, we suspect that the more likely
explanation is that some of our subjects were exposed to an
unidentified stimulus outside the laboratory that increased
GM-CSF levels.
The presence of GM-CSF is of interest to us because GM-
CSF is a cytokine that stimulates bonemarrow hematopoietic
stem cells to produce increased numbers of neutrophils,
eosinophils, basophils, and monocytes, in addition to pro-
moting dendritic cell maturation and antigen presentation.
Thus, GM-CSF-rich airway environments have been hypoth-
esized to promote the development of an immune response by
creating conditions conducive to TH2-cell differentiation and
that exposure to DPM and other particulates could support
the differentiation of TH2-cells through the induction of GM-
CSF [26, 27], which can promote TH2-cell proliferation by
enhancing the ability of dendritic cells to generate antigen
specific B and T-cell responses [28]. Our observation further
supports the existing literature demonstrating that DPM
exposure can increase expression of GM-CSF.
Finally, this study showed thatDPMmay act as an irritant,
as some of our subjects complained ofmild symptoms imme-
diately after exposure that were resolved by the 2 h time point.
Rudell et al. [20] looked at diesel exhaust as awhole and found
that it caused similar symptoms, potentially due to both
the gaseous and particulate components of diesel exhaust,
which are known irritants. In contrast, Nightingale et al. [4],
who examined DPM alone, reported no adverse symptoms;
they attributed this to the lack of gaseous components that
they believed were more likely to act as an irritant. Our
study contradicts this and suggests that the DPM alone is
also able to induce mild symptoms even in the absence
of the gaseous components of diesel exhaust. Our subjects
also spontaneously reported an itchy throat, with 6 out of
10 subjects complaining of this symptom after DMP300
exposure. Throat irritation is noted in other studies [20, 29].
The number of subjects who reported an itchy throat suggests
that this should be monitored in future studies. We cannot
rule out the possibility that the unblinded nature of our study
design meant that participants knew what dose they were
inhaling, thereby influencing the symptoms reported. Given
the imperative to safety in this pilot study this could not be
helped, as it was important to escalate from low to higher
doses, but future studies at these doses would benefit from
being blinded.
5. Conclusion
Overall, this novel method of inhaling nebulizedDPMmixed
in saline proved to be a safe and effective way to examine
the effects of DPM and our protocol provides a framework
for future research. Inhalation of nebulized DPM delivered
the particles to the lower airways and elicited transient
decrements in FEV
1
. However, even at the highest dose
of DPM administered in this study, we did not observe
cellular inflammatory responses in the airways and blood
and measured only very small changes in proinflammatory
cytokine levels. For studies aimed at examining inflammatory
responses, higher doses may be required but should be tested
carefully for safety, particularly in subjects whomay have air-
way hyperreactivity. Understanding themechanisms through
which airborne particulates influence inflammation and lung
function will help us to understand the correlation between
particulate exposure and increases in cardiopulmonary mor-
bidity and mortality that have been demonstrated epi-
demiologically. It may also help us identify the threshold
dose that is able to elicit an inflammatory response in
healthy and susceptible populations, which could be a critical
8 Journal of Respiratory Medicine
consideration in defining emission standards and workplace
policies.
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